Will Covid-19 antibodies actually matter?
A handful of drug companies, led by Regeneron Pharmaceuticals and Eli Lilly, are pressing forward with manmade antibodies that could treat and even prevent Covid-19. But as the world pours resources into an unprecedentedly fast vaccine effort, it’s increasingly unclear how useful those antibodies might be.
As STAT’s Matthew Herper and Adam Feuerstein report, the most advanced antibody projects are expected to generate early efficacy data in the coming months. The first studies will determine how much those antibodies benefit patients hospitalized with Covid-19. Later trials will determine whether they can function like vaccines, given to healthy people to prevent against a future infection.
But time might not be on their side. As former Food and Drug Administration Commissioner Scott Gottlieb points out, the federal government has prioritized vaccines over treatments for Covid-19, and if the administration’s ambitious goals come through, there may not be much need for antibodies by the time they’re ready for widespread use.
Read more.
As STAT’s Matthew Herper and Adam Feuerstein report, the most advanced antibody projects are expected to generate early efficacy data in the coming months. The first studies will determine how much those antibodies benefit patients hospitalized with Covid-19. Later trials will determine whether they can function like vaccines, given to healthy people to prevent against a future infection.
But time might not be on their side. As former Food and Drug Administration Commissioner Scott Gottlieb points out, the federal government has prioritized vaccines over treatments for Covid-19, and if the administration’s ambitious goals come through, there may not be much need for antibodies by the time they’re ready for widespread use.
Read more.
.png)
No hay comentarios:
Publicar un comentario